News from redhill biopharma ltd. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 09, 2023, 07:00 ET RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week

New Talicia PBPK modeling data, published in AP&T Journal, showed that generically substituted regimens are non-bioequivalent to Talicia Separately,...

May 01, 2023, 07:00 ET RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the granting of two new EU ...

Apr 28, 2023, 07:00 ET RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights

Having extinguished all debt and significantly reduced cost-base, RedHill is now focused on late-stage pipeline advancement, in collaboration with...

Apr 11, 2023, 07:00 ET RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received...

Mar 30, 2023, 08:00 ET RedHill Biopharma Announces $6 Million Registered Direct Offering

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a ...

Mar 21, 2023, 07:00 ET RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders

RedHill commits to reimburse out-of-pocket costs for Talicia patients that complete the full 14-day treatment course and whose infection is not...

Mar 08, 2023, 19:05 ET RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced agreement, with a single...

Feb 28, 2023, 07:00 ET RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program

The National Institutes of Health's (NIH) Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for testing via their radiation...

Feb 16, 2023, 08:00 ET RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that following a positive...

Feb 15, 2023, 07:00 ET RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome

FDA provided guidance on opaganib's regulatory pathway under the Animal Rule for Acute Radiation Syndrome (ARS) The FDA's Animal Rule allows for the...

Feb 06, 2023, 07:00 ET RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik®

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the extinguishment of all...

Jan 26, 2023, 07:00 ET RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease

Once issued, the patent is expected to extend protection of RHB-204 to 2041 RHB-204 is currently undergoing a Phase 3 study in the U.S. as the first...

Jan 03, 2023, 07:00 ET RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19

Positive data from a U.S. Phase 2 study of once-daily oral RHB-107 (upamostat) in symptomatic COVID-19 published in the peer-reviewed International...

Dec 02, 2022, 09:00 ET RedHill Biopharma Prices $8.0 Million Underwritten Public Offering

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the pricing of an...

Dec 01, 2022, 16:01 ET RedHill Biopharma Announces Proposed Public Offering

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it intends to offer...

Nov 29, 2022, 08:00 ET RedHill Biopharma Announces Q3/22 Results and Operational Highlights

Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt obligations, to facilitate growth Q3/22 Net revenues...

Nov 17, 2022, 08:30 ET RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury

Positive in vivo results from a new study of opaganib in radiation-induced hematologic and renal toxicity reaffirms opaganib's potential protective...

Nov 14, 2022, 06:00 ET RedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for Movantik®

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has reached a...

Nov 07, 2022, 09:49 ET RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates

Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022;...

Oct 26, 2022, 07:00 ET RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022

Physiologically-Based Pharmacokinetic (PBPK) modeling study of Talicia evaluated intragastric antibiotic exposure, critical for successful H. pylori...

Oct 19, 2022, 07:00 ET RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent

USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and receiving supplemental ...

Oct 18, 2022, 07:00 ET RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announces that on October 12, 2022, it...

Aug 17, 2022, 08:00 ET RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections

Developed as the first stand-alone standard of care first-line therapy for NTM disease caused by Mycobacterium avium complex (MAC) infection, RHB-204 ...

Jul 12, 2022, 08:00 ET RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences

Talicia® - World Gastro 2022 congress (August 17-18): RedHill invited to give prestigious oral presentation of important data detailing high...

Jun 23, 2022, 07:00 ET RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

Targeting positive cash from operations to start during H2/22[1] Focus on earlier achievement of operational profitability thanks to a recently...